Prevent polypharmacy problemsPolypharmacy presents real problems—especially for older adults.
USPSTF updates recommendations for aspirin useThe guidelines, which update the group's 2007 and 2009 recommendations, are published in the "Annals of Internal Medicine."
Unusual abdominal pain in an 8-year-old boyA previously healthy 8-year-old Hispanic boy presented to the emergency department (ED) with a 2-day history of abdominal pain and 2 episodes of nonprojectile vomiting in the last 24 hours.
Limb gangrene in cancer patients receiving warfarinVenous limb gangrene can occur in cancer patients, but the clinical picture and pathogenesis aren’t clear.
Aspirin recommended to prevent CVD, colorectal cancerAspirin should be taken daily in low doses by certain people to not only prevent heart disease and stroke, but also colon cancer, according to new draft guidelines.
New aspirin formulation approved for secondary prevention of stroke, cardiac eventsFDA approved aspirin extended release capsules (Durlaza, New Haven Pharmaceuticals, Inc.) for the prevention of stroke and acute cardiac events.
PCORI approves trial to determine best aspirin dose to help heart disease patientsThe Patient-Centered Outcomes Research Institute (PCORI) Board of Governors this week approved a 3-year, $14 million clinical trial designed to determine the best dose of aspirin to use to prevent heart attacks and strokes in people with heart disease.
Study: Genetic variants determine whether aspirin/NSAIDS will reduce colorectal cancer riskRegular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) appears to reduce the risk of colorectal cancer in most individuals, but a few individuals with rare genetic variants do not share this benefit, according to a study published in the March 17 issue of JAMA.
Evidence suggests no harmful effects of aspirin on AMD progressionObservational data from the AREDS2 study suggests that aspirin use is not associated with progression of age-related macular degeneration or development of geographic atrophy or neovascularization.
Post-MI NSAID/anticoag combo may increase risk of CV bleeding eventsAmong patients receiving antithrombotic therapy (to prevent the formation of blood clots) after a heart attack, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of bleeding and events such as heart attack, stroke or cardiovascular death, even after short-term treatment, according to a study in the February 24 issue of JAMA.